Experimental 'T cell Engager' takes on Hard-to-Treat cancers
Disease control
Ongoing
This early-phase trial is testing a new drug called IMA401, which helps the body's immune T cells attack cancer cells that have certain markers (MAGE-A4 or MAGE-A8). The study includes about 95 adults with advanced solid tumors that have come back or not responded to other treatm…
Phase: PHASE1 • Sponsor: Immatics Biotechnologies GmbH • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC